Oculis Holding AG
OCS
View Detailed Chart
19.220USD
-0.260-1.33%
Market hours （ET）Quotes delayed by 15 min
1.07BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.33%
5 Days
-10.83%
1 Month
+9.39%
6 Months
+1.85%
Year to Date
+13.06%
1 Year
+7.49%
View Detailed Chart
TradingKey Stock Score of Oculis Holding AG
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oculis Holding AG's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Strong Buy
Current Rating
40.571
Target Price
+110.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Oculis Holding AG Highlights
StrengthsRisks
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -7.34, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 16.41M shares, increasing 4.89% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 2.05K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Oculis Holding AG Info
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Ticker SymbolOCS
CompanyOculis Holding AG
CEODr. Riad Sherif, M.D.
Websitehttps://oculis.com/
Related Instruments
+1.70%
-0.80%
-0.74%
-6.92%
+1.24%
-0.72%
-0.27%
-1.71%
+5.38%
-4.01%
-2.41%
+0.57%
-0.04%
-0.35%
+13.40%
-0.12%
-0.63%
+0.76%
-0.68%
-2.08%Popular Symbols
